13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001816307
Total reported value
$962.2M
$962.2M
69 檔
16.0%
In Q1 2025, Silverarc Capital Management, LLC's U.S. equity holdings reached a combined market value of $962.2M, distributed across 69 disclosed stock positions.
Silverarc Capital Management, LLC executed strategic sector rebalancing during Q1 2025, establishing 52 new positions while fully exiting 78 holdings and trimming 0 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 7.09% | — | +5.79% | |
| 2 | ✓ | Merus N V | Stock-Other | 6.98% | — | +19.12% | |
| 3 | NUVL | Nuvalent Inc-a | Stock-Other | 6.37% | -3.71% | EXIT | |
| 4 | AKRO | Akero Therapeutics Inc | Stock-Other | 5.96% | — | -2.65% | |
| 5 | INSM | Insmed Inc | Stock-Healthcare | 5.01% | -0.22% | -13.66% | |
| 6 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 4.01% | -5.91% | EXIT | |
| 7 | VCYT | Veracyte Inc | Stock-Other | 3.84% | +1.35% | +25.94% | |
| 8 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.66% | +0.87% | +23.26% | |
| 9 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.29% | +0.64% | +6.41% | |
| 10 | URGN | UroGen Pharma Ltd. | Stock-Other | 3.12% | +2.22% | +23.27% | |
| 11 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.48% | — | -24.34% | |
| 12 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.43% | — | — | |
| 13 | ASND | Ascendis Pharma A/S | Stock-Other | 2.41% | -2.91% | EXIT | |
| 14 | IRON | Disc Medicine Inc | Stock-Other | 2.40% | -0.65% | +114.23% | |
| 15 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.35% | -0.59% | +74.85% | |
| 16 | ETNBGBP | 89bio Inc | Stock-Other | 2.25% | — | +1465.10% | |
| 17 | ERAS | Erasca Inc | Stock-Other | 2.06% | -0.66% | -2.33% | |
| 18 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.74% | — | +72.50% | |
| 19 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.64% | — | — | |
| 20 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.50% | — | +47.40% | |
| 21 | ✓ | Akero Therapeutics Inc | Stock-Other | 1.50% | — | -17.91% | |
| 22 | GOSS | Gossamer Bio Inc | Stock-Other | 1.42% | — | +2.41% | |
| 23 | GILD | Gilead Sciences Inc | Stock-Healthcare | 1.42% | — | +520.29% | |
| 24 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 1.42% | — | +19.48% | |
| 25 | ELUT | Elutia Inc | Stock-Other | 1.38% | -0.05% | +49.81% | |
| 26 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.29% | -0.06% | +129.02% | |
| 27 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.10% | — | — | |
| 28 | ✓ | Compugen LTD | Stock-Other | 0.86% | -0.01% | +78.25% | |
| 29 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.85% | — | +23.31% | |
| 30 | ALKS | Alkermes plc | Stock-Healthcare | 0.84% | -1.04% | — | |
| 31 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.83% | — | — | |
| 32 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.78% | — | — | |
| 33 | KURA | Kura Oncology Inc | Stock-Other | 0.78% | — | — | |
| 34 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.76% | -0.58% | EXIT | |
| 35 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.71% | -1.66% | — | |
| 36 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.70% | — | — | |
| 37 | CERS | Cerus CORP | Stock-Other | 0.70% | +0.46% | +54.77% | |
| 38 | TELA | Tela Bio Inc | Stock-Other | 0.69% | +0.03% | -9.60% | |
| 39 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.68% | -1.89% | EXIT | |
| 40 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.68% | +0.69% | -27.82% | |
| 41 | 2655787D | Blueprint Medicines CORP | Stock-Other | 0.68% | — | — | |
| 42 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.67% | — | +23.41% | |
| 43 | BNTC | Benitec Biopharma Inc | Stock-Other | 0.67% | +0.17% | — | |
| 44 | LQDA | Liquidia CORP | Stock-Other | 0.65% | — | — | |
| 45 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 0.63% | — | — | |
| 46 | ✓ | Stock-Other | 0.63% | — | — | ||
| 47 | ✓ | Soleno Therapeutics Inc | Stock-Other | 0.62% | — | — | |
| 48 | ✓ | Biodesix Inc | Stock-Other | 0.52% | — | -5.40% | |
| 49 | DCTH | Delcath Systems Inc | Stock-Other | 0.50% | — | +23.27% | |
| 50 | QURE | uniQure N.V. | Stock-Other | 0.44% | +0.50% | NEW |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | AKRO | Akero Therapeutics Inc | +5.6% | -2.65% | Add |
| 2 | ✓ | Merus N V | +4% | +19.12% | Add |
| 3 | 4XC1 | Kalvista Pharmaceuticals Inc | +3.9% | +177.53% | Add |
| 4 | SNDX | Syndax Pharmaceuticals Inc | +3% | +6.41% | Add |
| 5 | INSM | Insmed Inc | +2.8% | -13.66% | Add |
| 6 | ASND | Ascendis Pharma A/S | +2.1% | +47.12% | Add |
| 7 | ETNBGBP | 89bio Inc | +2% | +1465.10% | Add |
| 8 | WVE | Wave Life Sciences Ltd. | +1.4% | +72.50% | Add |
| 9 | VCYT | Veracyte Inc | +1.2% | +25.94% | Add |
| 10 | MDGL | Madrigal Pharmaceuticals Inc | +0.6% | — | Add |
| 11 | CERS | Cerus CORP | +0.5% | +54.77% | Add |
| 12 | QURE | uniQure N.V. | +0.3% | +103.40% | Add |
| 13 | ✓ | Compugen LTD | +0.1% | +78.25% | Add |
| 14 | KURA | Kura Oncology Inc | 0% | — | Add |
| 15 | DCTH | Delcath Systems Inc | -0.1% | +23.27% | Add |
| 16 | CLDX | Celldex Therapeutics Inc | -0.5% | -22.15% | Add |
| 17 | ✓ | Mersana Therapeutics Inc | -0.5% | — | Add |
| 18 | VRNA | Verona Pharma PLC - Adr | — | NEW | New buy |
| 19 | NUVL | Nuvalent Inc-a | — | NEW | New buy |
| 20 | RYTM | Rhythm Pharmaceuticals Inc | — | NEW | New buy |
| 21 | URGN | UroGen Pharma Ltd. | — | NEW | New buy |
| 22 | XBI | Ss Spdr S&p Biotech ETF | — | EXIT | Sold out |
| 23 | 290A | Chinook Therapeutics Inc | — | EXIT | Sold out |
| 24 | RNAGBP | Avidity Biosciences Inc | — | NEW | New buy |
| 25 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 26 | IRON | Disc Medicine Inc | — | NEW | New buy |
| 27 | ORIC | Oric Pharmaceuticals Inc | — | NEW | New buy |
| 28 | ERAS | Erasca Inc | — | NEW | New buy |
| 29 | DRNAUSD | Dicerna Pharmaceuticals Inc | — | EXIT | Sold out |
| 30 | NBIX | Neurocrine Biosciences Inc | — | NEW | New buy |
| 31 | TVTX | Travere Therapeutics Inc | — | NEW | New buy |
| 32 | ✓ | Akero Therapeutics Inc | — | NEW | New buy |
| 33 | GOSS | Gossamer Bio Inc | — | NEW | New buy |
| 34 | GILD | Gilead Sciences Inc | — | NEW | New buy |
| 35 | ✓ | Helix Acquisition CORP Ii | — | NEW | New buy |
| 36 | ELUT | Elutia Inc | — | NEW | New buy |
| 37 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 38 | MRTXEUR | Mirati Therapeutics Inc | — | EXIT | Sold out |
| 39 | MORFUSD | Morphic Holding Inc | — | EXIT | Sold out |
| 40 | ✓ | Amryt Pharma LTD - Spnr Adr | — | EXIT | Sold out |
| 41 | BHVN | Biohaven Ltd. | — | EXIT | Sold out |
| 42 | IMGNEUR | Immunogen Inc | — | EXIT | Sold out |
| 43 | MLYS | Mineralys Therapeutics Inc | — | NEW | New buy |
| 44 | ✓ | Research Alliance CORP Ii | — | EXIT | Sold out |
| 45 | MGNX | Macrogenics Inc | — | EXIT | Sold out |
| 46 | ✓ | Horizon Therapeutics PLC | — | EXIT | Sold out |
| 47 | ITCIEUR | Intra-cellular Therapies Inc | — | EXIT | Sold out |
| 48 | MCRB1EUR | Seres Therapeutics Inc | — | EXIT | Sold out |
| 49 | ✓ | Veralto CORP | — | EXIT | Sold out |
| 50 | TARS | Tarsus Pharmaceuticals Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Silverarc Capital Management, LLC reported a total U.S. public equity portfolio value of $962.2M across 69 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VRNA, MERUS N V, NUVL) accounted for 16.0% of total reported equity market value during Q1 2025.
Top New Position Initiated
VRNA
市值: $34.7M
Top Position Liquidated / Trimmed
XBI
前期市值: $12.8M
During Q1 2025, Silverarc Capital Management, LLC's top holdings by market value included VRNA (7.1%)、MERUS N V (7.0%)、NUVL (6.4%). The largest single position, VRNA, represented 7.1% of total portfolio value.
In Q1 2025, Silverarc Capital Management, LLC made 147 total portfolio adjustments, initiating 52 new buys, adding to 17 positions, trimming 0 holdings, and fully liquidating 78 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.